Biju Kunhiraman, MD
Endocrinology, Diabetes & Metabolism · Yakima, WANPI 1740221506
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $101,650 of the $117,638 with a category attached, or 86.4%. 14 manufacturers reported payments, led by Novo Nordisk at 53.1% of the total. Among endocrinology, diabetes & metabolism clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 398 payments — averaging $295.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$62K
- AstraZeneca$45K
- Lilly USA, LLC$9K
- Dexcom, Inc.$268
- Bayer$177
- Boehringer Ingelheim$129
- plus $457 from 8 others
What the payments were for
- Speaking & faculty fees$101,65086%
- Travel & lodging$10,6709%
- Food & beverage$5,3065%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 277 | $62,436 |
| AstraZeneca | 82 | $45,489 |
| Lilly USA, LLC | 10 | $8,683 |
| Dexcom, Inc. | 3 | $268 |
| Bayer | 7 | $177 |
| Boehringer Ingelheim | 2 | $129 |
| Johnson & Johnson | 2 | $118 |
| Sanofi-aventis U.S. LLC | 6 | $91 |
| Tandem Diabetes Care, Inc. | 1 | $73 |
| Medtronic | 3 | $69 |
| Amgen | 2 | $42 |
| Lifescan, Inc. | 1 | $25 |
| BETA Bionics, Inc. | 1 | $22 |
| Merck | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$117,638 in reported general payments places this provider in the 95th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 200 | $332,026 |
| JardianceEmpagliflozin | 66 | $90,172 |
| Humalog Kwikpen U-200Insulin Lispro | 35 | $82,328 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $79,171 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $79,061 |
| TrulicityDulaglutide | 64 | $68,965 |
| FarxigaDapagliflozin Propanediol | 55 | $62,717 |
| MounjaroTirzepatide | 31 | $52,985 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 69 | $51,712 |
| Humalog Kwikpen U-100Insulin Lispro | 114 | $46,320 |
| Lyumjev Kwikpen U-200Insulin Lispro-Aabc | 17 | $35,053 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 35 | $33,849 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 28 | $30,071 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 138 | $29,675 |
| FiaspInsulin Aspart (Niacinamide) | 22 | $28,911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus | $62,436 | $387,810241 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $8,683 | $133,143126 claims |
| Boehringer IngelheimJardiance | $129 | $90,17266 claims |
| AstraZenecaFarxiga | $45,489 | $62,71755 claims |
| Sanofi-aventis U.S. LLCLantus | $91 | $5,52421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
Other endocrinology, diabetes & metabolism in Yakima
- Michael ShannonLacey$698K
- Lynn KohlmeierSpokane$518K
- Carol WyshamSpokane$512K
- Bruce WilsonRichland$352K
- Irl HirschSeattle$192K
- Nicole EhrhardtSeattle$111K
- Kristina UtzschneiderSeattle$72K
- Savitha SubramanianSeattle$71K
- Sonia HansKirkland$70K
- George MooreBothell$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.